Trials / Completed
CompletedNCT01358760
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 450 (actual)
- Sponsor
- EndoCeutics Inc. · Industry
- Sex
- Female
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Phase III trial is to evaluate the efficacy of intravaginal dehydroepiandrosterone (DHEA) in postmenopausal women with vaginal atrophy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo vaginal suppository |
| DRUG | DHEA | Vaginal suppository containing 0.25% (3.25 mg) DHEA |
| DRUG | DHEA | Vaginal suppository containing 0.5% (6.5 mg) DHEA |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2012-04-01
- Completion
- 2012-05-01
- First posted
- 2011-05-24
- Last updated
- 2017-06-12
- Results posted
- 2017-06-12
Locations
42 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01358760. Inclusion in this directory is not an endorsement.